Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

[Spinal Muscular Atrophy - expert recommendations for the use of nusinersen in adult patients].

Hagenacker T, Hermann A, Kamm C, Walter MC, Weiler M, Günther R, Wurster CD, Kleinschnitz C.

Fortschr Neurol Psychiatr. 2019 Dec;87(12):703-710. doi: 10.1055/a-0996-0994. Epub 2019 Dec 17. German.

PMID:
31847032
2.

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen.

Wurster CD, Koch JC, Cordts I, Dreyhaupt J, Otto M, Uzelac Z, Witzel S, Winter B, Kocak T, Schocke M, Weydt P, Wollinsky K, Ludolph AC, Deschauer M, Lingor P, Tumani H, Hermann A, Günther R.

Front Neurol. 2019 Nov 7;10:1179. doi: 10.3389/fneur.2019.01179. eCollection 2019.

3.

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy.

Günther R, Wurster CD, Cordts I, Koch JC, Kamm C, Petzold D, Aust E, Deschauer M, Lingor P, Ludolph AC, Hermann A.

Front Neurol. 2019 Nov 1;10:1098. doi: 10.3389/fneur.2019.01098. eCollection 2019.

4.

Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Wurster CD, Steinacker P, Günther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M; MND-Net.

J Neurol. 2020 Jan;267(1):36-44. doi: 10.1007/s00415-019-09547-y. Epub 2019 Sep 24.

PMID:
31552549
5.

Therapeutic advances in SMA.

Ludolph AC, Wurster CD.

Curr Opin Neurol. 2019 Oct;32(5):777-781. doi: 10.1097/WCO.0000000000000738.

PMID:
31425176
6.

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.

Wurster CD, Günther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M.

Ther Adv Neurol Disord. 2019 May 10;12:1756286419846058. doi: 10.1177/1756286419846058. eCollection 2019.

7.

Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen.

Winter B, Guenther R, Ludolph AC, Hermann A, Otto M, Wurster CD.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1068-1069. doi: 10.1136/jnnp-2018-320033. Epub 2019 Jan 10. No abstract available.

PMID:
30630960
8.

[Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience].

Walter MC, Dräger B, Günther R, Hermann A, Hagenacker T, Kleinschnitz C, Löscher W, Meyer T, Schrank B, Schwersenz I, Wurster CD, Ludolph AC, Kirschner J.

Nervenarzt. 2019 Apr;90(4):343-351. doi: 10.1007/s00115-018-0653-7. Review. German.

PMID:
30617569
9.

Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients.

Wurster CD, Winter B, Wollinsky K, Ludolph AC, Uzelac Z, Witzel S, Schocke M, Schneider R, Kocak T.

J Neurol. 2019 Jan;266(1):183-194. doi: 10.1007/s00415-018-9124-0. Epub 2018 Nov 20.

PMID:
30460449
10.

Antisense Oligonucleotides in Psychiatric Disorders.

Graf H, Wurster CD.

J Clin Psychopharmacol. 2018 Dec;38(6):651-652. doi: 10.1097/JCP.0000000000000969. No abstract available.

PMID:
30286000
11.

Antisense oligonucleotides in neurological disorders.

Wurster CD, Ludolph AC.

Ther Adv Neurol Disord. 2018 May 23;11:1756286418776932. doi: 10.1177/1756286418776932. eCollection 2018. Review.

12.

Nusinersen for spinal muscular atrophy.

Wurster CD, Ludolph AC.

Ther Adv Neurol Disord. 2018 Mar 13;11:1756285618754459. doi: 10.1177/1756285618754459. eCollection 2018. No abstract available.

13.

Neural correlates of rate-dependent finger-tapping in Parkinson's disease.

Wurster CD, Graf H, Ackermann H, Groth K, Kassubek J, Riecker A.

Brain Struct Funct. 2015;220(3):1637-48. doi: 10.1007/s00429-014-0749-1. Epub 2014 Mar 20.

PMID:
24647755

Supplemental Content

Loading ...
Support Center